{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:05:39Z","timestamp":1793970339454,"version":"4.8.0"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273512"],"award-info":[{"award-number":["82273512"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473517"],"award-info":[{"award-number":["82473517"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82430101"],"award-info":[{"award-number":["82430101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273510"],"award-info":[{"award-number":["82273510"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Research and Development Program of China","award":["2023YFC2508106"],"award-info":[{"award-number":["2023YFC2508106"]}]},{"name":"Innovation Program of Shanghai Municipal Education Commission","award":["2025GDZKZD06"],"award-info":[{"award-number":["2025GDZKZD06"]}]},{"name":"Shanghai Dermatology Research Center","award":["2023ZZ02017"],"award-info":[{"award-number":["2023ZZ02017"]}]},{"name":"Clinical Cohort Shanghai","award":["SHDC2025CCS013"],"award-info":[{"award-number":["SHDC2025CCS013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40265-026-02354-6","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:57:34Z","timestamp":1782305854000},"page":"1435-1452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions"],"prefix":"10.1007","volume":"86","author":[{"given":"Yue","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangluyi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanting","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengkai","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5204-4086","authenticated-orcid":false,"given":"Xilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"2354_CR1","unstructured":"Aboud DMA, Nessel TA, Hafsi W. Cutaneous adverse drug reaction. In: StatPearls. Treasure Island: StatPearls Publishing; 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK533000. Accessed 29 Jan 2026."},{"key":"2354_CR2","volume-title":"Dermatology","author":"JL Bolognia","year":"2024","unstructured":"Bolognia JL, Schaffer JV, Cerroni L. Dermatology. 5th ed. Philadelphia: Elsevier; 2024.","edition":"5"},{"key":"2354_CR3","doi-asserted-by":"publisher","unstructured":"Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol. 2014;71(2):203.e1\u2013e12. https:\/\/doi.org\/10.1016\/j.jaad.2014.04.014(quiz 215\u2013216).","DOI":"10.1016\/j.jaad.2014.04.014"},{"key":"2354_CR4","doi-asserted-by":"publisher","unstructured":"Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: part II. Targeted therapy. J Am Acad Dermatol. 2014;71(2):217.e1\u2013e11. https:\/\/doi.org\/10.1016\/j.jaad.2014.04.013(quiz 227\u2013228).","DOI":"10.1016\/j.jaad.2014.04.013"},{"issue":"8","key":"2354_CR5","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1111\/bcp.15490","volume":"90","author":"BR Del Pozzo-Maga\u00f1a","year":"2024","unstructured":"Del Pozzo-Maga\u00f1a BR, Liy-Wong C. Drugs and the skin: a concise review of cutaneous adverse drug reactions. Br J Clin Pharmacol. 2024;90(8):1838\u201355. https:\/\/doi.org\/10.1111\/bcp.15490.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2354_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-024-00514-0","volume":"10","author":"SI Hung","year":"2024","unstructured":"Hung SI, Mockenhaupt M, Blumenthal KG, Abe R, Ueta M, Ingen-Housz-Oro S, et al. Severe cutaneous adverse reactions. Nat Rev Dis Primers. 2024;10(1):30. https:\/\/doi.org\/10.1038\/s41572-024-00514-0.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"2354_CR7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40257-024-00866-z","volume":"25","author":"J Pach","year":"2024","unstructured":"Pach J, Valido K, Belzer A, Leventhal JS. The use of biologic agents for the treatment of cutaneous immune-related adverse events from immune checkpoint inhibitors: a review of reported cases. Am J Clin Dermatol. 2024;25(4):595\u2013607. https:\/\/doi.org\/10.1007\/s40257-024-00866-z.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"2354_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60\u20133. https:\/\/doi.org\/10.1136\/bmjebm-2017-110853.","journal-title":"BMJ Evid Based Med."},{"issue":"4","key":"2354_CR9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/aci.0000000000000180","volume":"15","author":"T Shiohara","year":"2015","unstructured":"Shiohara T, Mizukawa Y, Aoyama Y. Monitoring the acute response in severe hypersensitivity reactions to drugs. Curr Opin Allergy Clin Immunol. 2015;15(4):294\u20139. https:\/\/doi.org\/10.1097\/aci.0000000000000180.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2354_CR10","doi-asserted-by":"publisher","first-page":"6431694","DOI":"10.1155\/2018\/6431694","volume":"2018","author":"CB Chen","year":"2018","unstructured":"Chen CB, Abe R, Pan RY, Wang CW, Hung SI, Tsai YG, et al. An updated review of the molecular mechanisms in drug hypersensitivity. J Immunol Res. 2018;2018:6431694. https:\/\/doi.org\/10.1155\/2018\/6431694.","journal-title":"J Immunol Res"},{"issue":"4","key":"2354_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1468-3083.2010.03771.x","volume":"25","author":"R Kabashima","year":"2011","unstructured":"Kabashima R, Sugita K, Sawada Y, Hino R, Nakamura M, Tokura Y. Increased circulating Th17 frequencies and serum IL-22 levels in patients with acute generalized exanthematous pustulosis. J Eur Acad Dermatol Venereol. 2011;25(4):485\u20138. https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03771.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"2354_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.5021\/ad.2016.28.4.451","volume":"28","author":"HS Song","year":"2016","unstructured":"Song HS, Kim SJ, Park TI, Jang YH, Lee ES. Immunohistochemical comparison of IL-36 and the IL-23\/Th17 axis of generalized pustular psoriasis and acute generalized exanthematous pustulosis. Ann Dermatol. 2016;28(4):451\u20136. https:\/\/doi.org\/10.5021\/ad.2016.28.4.451.","journal-title":"Ann Dermatol"},{"issue":"12","key":"2354_CR13","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/nm.1884","volume":"14","author":"WH Chung","year":"2008","unstructured":"Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343\u201350. https:\/\/doi.org\/10.1038\/nm.1884.","journal-title":"Nat Med"},{"issue":"5388","key":"2354_CR14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1126\/science.282.5388.490","volume":"282","author":"I Viard","year":"1998","unstructured":"Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 5388;282(5388):490\u20133. https:\/\/doi.org\/10.1126\/science.282.5388.490.","journal-title":"Science"},{"issue":"2","key":"2354_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/jid.2012.330","volume":"133","author":"I Viard-Leveugle","year":"2013","unstructured":"Viard-Leveugle I, Gaide O, Jankovic D, Feldmeyer L, Kerl K, Pickard C, et al. TNF-\u03b1 and IFN-\u03b3 are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol. 2013;133(2):489\u201398. https:\/\/doi.org\/10.1038\/jid.2012.330.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"2354_CR16","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jid.2016.11.034","volume":"137","author":"SC Su","year":"2017","unstructured":"Su SC, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S, Chen CB, et al. Interleukin-15 is associated with severity and mortality in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis. J Invest Dermatol. 2017;137(5):1065\u201373. https:\/\/doi.org\/10.1016\/j.jid.2016.11.034.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"2354_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10081868","volume":"10","author":"T Bell\u00f3n","year":"2022","unstructured":"Bell\u00f3n T, Gonz\u00e1lez-Valle O, Sendagorta E, Lerma V, Mart\u00ednez Del R\u00edo J, Mart\u00ednez C, et al. IL-15\/IL-15R\u03b1 in SJS\/TEN: relevant expression of IL15 and IL15RA in affected skin. Biomedicines. 2022;10(8):1868. https:\/\/doi.org\/10.3390\/biomedicines10081868.","journal-title":"Biomedicines"},{"issue":"2","key":"2354_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1600-0625.2010.01176.x","volume":"20","author":"E de Araujo","year":"2011","unstructured":"de Araujo E, Dessirier V, Lapr\u00e9e G, Valeyrie-Allanore L, Ortonne N, Stathopoulos EN, et al. Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol. 2011;20(2):107\u201312. https:\/\/doi.org\/10.1111\/j.1600-0625.2010.01176.x.","journal-title":"Exp Dermatol"},{"issue":"8","key":"2354_CR19","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.jid.2018.10.048","volume":"139","author":"YG Tsai","year":"2019","unstructured":"Tsai YG, Liou JH, Hung SI, Chen CB, Chiu TM, Wang CW, et al. Increased type 2 innate lymphoid cells in patients with drug reaction with eosinophilia and systemic symptoms syndrome. J Invest Dermatol. 2019;139(8):1722\u201331. https:\/\/doi.org\/10.1016\/j.jid.2018.10.048.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2354_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jcmgh.2017.01.005","volume":"3","author":"K Tsilingiri","year":"2017","unstructured":"Tsilingiri K, Fornasa G, Rescigno M. Thymic stromal lymphopoietin: to cut a long story short. Cell Mol Gastroenterol Hepatol. 2017;3(2):174\u201382. https:\/\/doi.org\/10.1016\/j.jcmgh.2017.01.005.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2354_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2016.05.004","volume":"42","author":"C Hardman","year":"2016","unstructured":"Hardman C, Ogg G. Interleukin-33, friend and foe in type-2 immune responses. Curr Opin Immunol. 2016;42:16\u201324. https:\/\/doi.org\/10.1016\/j.coi.2016.05.004.","journal-title":"Curr Opin Immunol"},{"issue":"12","key":"2354_CR22","doi-asserted-by":"publisher","first-page":"8071","DOI":"10.4049\/jimmunol.0804002","volume":"182","author":"R Takahashi","year":"2009","unstructured":"Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol. 2009;182(12):8071\u20139. https:\/\/doi.org\/10.4049\/jimmunol.0804002.","journal-title":"J Immunol"},{"issue":"2 Pt 1","key":"2354_CR23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/s0190-9622(88)70050-x","volume":"18","author":"J Alcalay","year":"1988","unstructured":"Alcalay J, David M, Ingber A, Hazaz B, Sandbank M. Bullous pemphigoid mimicking bullous erythema multiforme: an untoward side effect of penicillins. J Am Acad Dermatol. 1988;9622(88):345\u20139. https:\/\/doi.org\/10.1016\/s0190-9622(88)70050-x.","journal-title":"J Am Acad Dermatol"},{"issue":"15","key":"2354_CR24","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3457","volume":"100","author":"MJ Verheyden","year":"2020","unstructured":"Verheyden MJ, Bilgic A, Murrell DF. A systematic review of drug-induced pemphigoid. Acta Derm Venereol. 2020;100(15):adv00224. https:\/\/doi.org\/10.2340\/00015555-3457.","journal-title":"Acta Derm Venereol"},{"issue":"23","key":"2354_CR25","doi-asserted-by":"publisher","first-page":"16786","DOI":"10.3390\/ijms242316786","volume":"24","author":"B de Nicolas-Ruanes","year":"2023","unstructured":"de Nicolas-Ruanes B, Ballester-Martinez A, Garcia-Mouronte E, Berna-Rico E, Azcarraga-Llobet C, Fernandez-Guarino M. From molecular insights to clinical perspectives in drug-associated bullous pemphigoid. Int J Mol Sci. 2023;24(23):16786. https:\/\/doi.org\/10.3390\/ijms242316786.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2354_CR26","doi-asserted-by":"publisher","first-page":"2280991","DOI":"10.1080\/07853890.2023.2280991","volume":"55","author":"R Huang","year":"2023","unstructured":"Huang R, Hu L, Jiang F. Study of cytokine-induced immunity in bullous pemphigoid: recent developments. Ann Med. 2023;55(2):2280991. https:\/\/doi.org\/10.1080\/07853890.2023.2280991.","journal-title":"Ann Med"},{"issue":"1","key":"2354_CR27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41392-024-01934-w","volume":"9","author":"Y Lv","year":"2024","unstructured":"Lv Y, Qi J, Babon JJ, Cao L, Fan G, Lang J, et al. The JAK-STAT pathway: from structural biology to cytokine engineering. Signal Transduct Target Ther. 2024;9(1):221. https:\/\/doi.org\/10.1038\/s41392-024-01934-w.","journal-title":"Signal Transduct Target Ther"},{"key":"2354_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111846","volume":"131","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang Z, Li S, Ma J, Dai X, Lu J. Deciphering JAK\/STAT signaling pathway: a multifaceted approach to tumorigenesis, progression and therapeutic interventions. Int Immunopharmacol. 2024;131:111846. https:\/\/doi.org\/10.1016\/j.intimp.2024.111846.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"2354_CR29","doi-asserted-by":"publisher","first-page":"S270","DOI":"10.1016\/j.jid.2023.03.1590","volume":"143","author":"G Velasquez","year":"2023","unstructured":"Velasquez G, Shah P, Romar G, Mousad L, Boer L, Schmidt B, et al. 1573 JAK inhibition may prevent drug hypersensitivity reactions. J Invest Dermatol. 2023;143(5):S270. https:\/\/doi.org\/10.1016\/j.jid.2023.03.1590.","journal-title":"J Invest Dermatol"},{"issue":"8040","key":"2354_CR30","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41586-024-08061-0","volume":"635","author":"TM Nordmann","year":"2024","unstructured":"Nordmann TM, Anderton H, Hasegawa A, Schweizer L, Zhang P, Stadler PC, et al. Spatial proteomics identifies JAKi as treatment for a lethal skin disease. Nature. 2024;635(8040):1001\u20139. https:\/\/doi.org\/10.1038\/s41586-024-08061-0.","journal-title":"Nature"},{"issue":"2","key":"2354_CR31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41591-019-0733-7","volume":"26","author":"D Kim","year":"2020","unstructured":"Kim D, Kobayashi T, Voisin B, Jo JH, Sakamoto K, Jin SP, et al. Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report. Nat Med. 2020;26(2):236\u201343. https:\/\/doi.org\/10.1038\/s41591-019-0733-7.","journal-title":"Nat Med"},{"issue":"3","key":"2354_CR32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1093\/bjd\/ljaf219","volume":"193","author":"HY Chung","year":"2025","unstructured":"Chung HY, Chen CB, Lee HE, Lu CW, Chen WT, Hui RC, et al. Janus kinase\/signal transducer and activator of transcription signalling pathway is involved in the immune mechanism of bullous pemphigoid. Br J Dermatol. 2025;193(3):521\u201331. https:\/\/doi.org\/10.1093\/bjd\/ljaf219.","journal-title":"Br J Dermatol"},{"key":"2354_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","volume":"101","author":"H Mitoma","year":"2018","unstructured":"Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-\u03b1 agents\u2014comparison among therapeutic TNF-\u03b1 antagonists. Cytokine. 2018;101:56\u201363. https:\/\/doi.org\/10.1016\/j.cyto.2016.08.014.","journal-title":"Cytokine"},{"issue":"3","key":"2354_CR34","doi-asserted-by":"publisher","first-page":"G612","DOI":"10.1152\/ajpgi.90576.2008","volume":"296","author":"EC Ebert","year":"2009","unstructured":"Ebert EC. Infliximab and the TNF-alpha system. Am J Physiol Gastrointest Liver Physiol. 2009;296(3):G612\u201320. https:\/\/doi.org\/10.1152\/ajpgi.90576.2008.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"6","key":"2354_CR35","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s13555-023-00928-w","volume":"13","author":"J Cao","year":"2023","unstructured":"Cao J, Zhang X, Xing X, Fan J. Biologic TNF-\u03b1 inhibitors for Stevens\u2013Johnson syndrome, toxic epidermal necrolysis, and TEN-SJS overlap: a study-level and patient-level meta-analysis. Dermatol Ther (Heidelb). 2023;13(6):1305\u201327. https:\/\/doi.org\/10.1007\/s13555-023-00928-w.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"5","key":"2354_CR36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1684\/ejd.2020.3883","volume":"30","author":"A Paradisi","year":"2020","unstructured":"Paradisi A, Abeni D, Didona D, Ricci F, Canzona F, Didona B. A new case series on etanercept treatment for toxic epidermal necrolysis. Eur J Dermatol. 2020;30(5):561\u20138. https:\/\/doi.org\/10.1684\/ejd.2020.3883.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"2354_CR37","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","volume":"71","author":"A Paradisi","year":"2014","unstructured":"Paradisi A, Abeni D, Bergamo F, Ricci F, Didona D, Didona B. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014;71(2):278\u201383. https:\/\/doi.org\/10.1016\/j.jaad.2014.04.044.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2354_CR38","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.anai.2022.05.009","volume":"129","author":"CC Tian","year":"2022","unstructured":"Tian CC, Ai XC, Ma JC, Hu FQ, Liu XT, Luo YJ, et al. Etanercept treatment of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol. 2022;129(3):360-5.e1. https:\/\/doi.org\/10.1016\/j.anai.2022.05.009.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"2354_CR39","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jaip.2022.01.038","volume":"10","author":"J Zhang","year":"2022","unstructured":"Zhang J, Lu CW, Chen CB, Wang CW, Chen WT, Cheng B, et al. Evaluation of combination therapy with etanercept and systemic corticosteroids for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a multicenter observational study. J Allergy Clin Immunol Pract. 2022;10(5):1295-304.e6. https:\/\/doi.org\/10.1016\/j.jaip.2022.01.038.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"2354_CR40","doi-asserted-by":"publisher","first-page":"10733","DOI":"10.1038\/s41467-024-54180-7","volume":"15","author":"CB Chen","year":"2024","unstructured":"Chen CB, Hung SI, Chang JW, Yang CK, Ma DH, Teng YC, et al. Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade. Nat Commun. 2024;15(1):10733. https:\/\/doi.org\/10.1038\/s41467-024-54180-7.","journal-title":"Nat Commun"},{"key":"2354_CR41","doi-asserted-by":"publisher","first-page":"1342898","DOI":"10.3389\/fimmu.2024.1342898","volume":"15","author":"MS Jeong","year":"2024","unstructured":"Jeong MS, Choi YY, Ahn YH, Lee K, Park JS, Suh DI. Etanercept treatment for pediatric toxic epidermal necrolysis induced by deflazacort: a case report and literature review. Front Immunol. 2024;15:1342898. https:\/\/doi.org\/10.3389\/fimmu.2024.1342898.","journal-title":"Front Immunol"},{"issue":"5","key":"2354_CR42","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1177\/1203475418758989","volume":"22","author":"GM Gavigan","year":"2018","unstructured":"Gavigan GM, Kanigsberg ND, Ramien ML. Pediatric Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis halted by etanercept. J Cutan Med Surg. 2018;22(5):514\u20135. https:\/\/doi.org\/10.1177\/1203475418758989.","journal-title":"J Cutan Med Surg"},{"issue":"11","key":"2354_CR43","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/1346-8138.15058","volume":"46","author":"F Wang","year":"2019","unstructured":"Wang F, Gao X, Chen X, Tang X, Chen H, Han J. Successful treatment of interstitial lung disease related to Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis overlap with etanercept: a case report and published work review. J Dermatol. 2019;46(11):1035\u20138. https:\/\/doi.org\/10.1111\/1346-8138.15058.","journal-title":"J Dermatol"},{"issue":"1","key":"2354_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.185","volume":"3","author":"K Yordanova","year":"2023","unstructured":"Yordanova K, Pf\u00f6hler C, Schweitzer LF, Bourg C, Adam L, Vogt T. Etanercept leads to a rapid recovery of a dabrafenib-\/trametinib-associated toxic epidermal necrolysis-like severe skin reaction. Skin Health Dis. 2023;3(1):e185. https:\/\/doi.org\/10.1002\/ski2.185.","journal-title":"Skin Health Dis."},{"issue":"4","key":"2354_CR45","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/09546630802683843","volume":"20","author":"G Gencoglan","year":"2009","unstructured":"Gencoglan G, Tosun M, Aktepe F. The molecular mechanism of etanercept, an anti-tumour necrosis factor-alpha receptor-fusion protein, in the treatment of acute generalized exanthematous pustulosis. J Dermatolog Treat. 2009;20(4):241\u20135. https:\/\/doi.org\/10.1080\/09546630802683843.","journal-title":"J Dermatolog Treat"},{"key":"2354_CR46","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/601412","volume":"2013","author":"M Kavala","year":"2013","unstructured":"Kavala M, Zindanc\u0131 I, T\u00fcrkoglu Z, Can B, Kocat\u00fcrk E, Senol S, et al. Acute generalized exanthematous pustulosis induced by etanercept: another dermatologic adverse effect. Case Rep Dermatol Med. 2013;2013:601412. https:\/\/doi.org\/10.1155\/2013\/601412.","journal-title":"Case Rep Dermatol Med."},{"key":"2354_CR47","doi-asserted-by":"crossref","unstructured":"Barrientos N, Garc\u00eda-S\u00e1nchez S, Dom\u00ednguez JD. Letter: lichenoid eruption induced by etanercept. Dermatol Online J. 2012;18(7):15. https:\/\/escholarship.org\/uc\/item\/1s58n0k3","DOI":"10.5070\/D32FW0W71N"},{"key":"2354_CR48","doi-asserted-by":"publisher","unstructured":"Kara A, Alatas ET, Celebi HS, Dogan G, Dere Y. Pustular eruption induced by etanercept in a patient with ankylosing spondylitis: a rare side effect. N Clin Istanb. 2015;2(3):231\u20135. https:\/\/doi.org\/10.14744\/nci.2015.95914.","DOI":"10.14744\/nci.2015.95914"},{"issue":"1","key":"2354_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jdcr.2015.12.006","volume":"2","author":"EN Wilmer","year":"2016","unstructured":"Wilmer EN, Becker N, Chen A, Kroumpouzos G. Etanercept-induced generalization of chronic, localized, anogenital bullous pemphigoid in a psoriatic patient. JAAD Case Rep. 2016;2(1):25\u20137. https:\/\/doi.org\/10.1016\/j.jdcr.2015.12.006.","journal-title":"JAAD Case Rep."},{"issue":"4","key":"2354_CR50","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","volume":"146","author":"M Fischer","year":"2002","unstructured":"Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol. 2002;146(4):707\u20139. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.46833.x.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2354_CR51","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/pde.13778","volume":"36","author":"L Chafranska","year":"2019","unstructured":"Chafranska L, Saunte DM, Behrendt N, Nygaard U, Christensen RJ, Sand C, et al. Pediatric toxic epidermal necrolysis treated successfully with infliximab. Pediatr Dermatol. 2019;36(3):342\u20135. https:\/\/doi.org\/10.1111\/pde.13778.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"2354_CR52","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/ijd.13924","volume":"57","author":"YY Jiang","year":"2018","unstructured":"Jiang YY, Nguyen GH, Jin HZ, Zeng YP. Methazolamide-induced toxic epidermal necrolysis in a man carrying HLA-B*59:01: successful treatment with infliximab and glucocorticoid. Int J Dermatol. 2018;57(4):494\u20136. https:\/\/doi.org\/10.1111\/ijd.13924.","journal-title":"Int J Dermatol"},{"key":"2354_CR53","doi-asserted-by":"publisher","first-page":"1580170","DOI":"10.3389\/fphar.2025.1580170","volume":"16","author":"X Jiang","year":"2025","unstructured":"Jiang X, Hua C, Feng C, Cheng H. Case report: infliximab for hydroxychloroquine-induced AGEP with IL17A and IL36RN mutations: a case report and management considerations. Front Pharmacol. 2025;16:1580170. https:\/\/doi.org\/10.3389\/fphar.2025.1580170.","journal-title":"Front Pharmacol"},{"issue":"5","key":"2354_CR54","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1468-3083.2006.02026.x","volume":"21","author":"F Meiss","year":"2007","unstructured":"Meiss F, Helmbold P, Meykadeh N, Gaber G, Marsch W, Fischer M. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases. J Eur Acad Dermatol Venereol. 2007;21(5):717\u20139. https:\/\/doi.org\/10.1111\/j.1468-3083.2006.02026.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"2354_CR55","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12554","volume":"30","author":"S Senil\u0103","year":"2017","unstructured":"Senil\u0103 S, Seicean A, Fechete O, Grad A, Ungureanu L. Infliximab-induced acne and acute localized exanthematous pustulosis: case report. Dermatol Ther. 2017;30(6):e12554. https:\/\/doi.org\/10.1111\/dth.12554.","journal-title":"Dermatol Ther"},{"issue":"9","key":"2354_CR56","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1136\/annrheumdis-2015-207477","volume":"75","author":"NC Brembilla","year":"2016","unstructured":"Brembilla NC, Dufour AM, Alvarez M, Hugues S, Montanari E, Truchetet ME, et al. IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. Ann Rheum Dis. 2016;75(9):1697\u2013705. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207477.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2354_CR57","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s10165-011-0550-4","volume":"22","author":"J Ram\u00edrez","year":"2012","unstructured":"Ram\u00edrez J, Hern\u00e1ndez MV, Galve J, Ca\u00f1ete JD, Sanmart\u00ed R. Morphea associated with the use of adalimumab: a case report and review of the literature. Mod Rheumatol. 2012;22(4):602\u20134. https:\/\/doi.org\/10.1007\/s10165-011-0550-4.","journal-title":"Mod Rheumatol"},{"key":"2354_CR58","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ejca.2019.05.018","volume":"116","author":"H Herrscher","year":"2019","unstructured":"Herrscher H, Tomasic G, Castro GA. Generalised morphea induced by pembrolizumab. Eur J Cancer. 2019;116:178\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2019.05.018.","journal-title":"Eur J Cancer"},{"key":"2354_CR59","doi-asserted-by":"publisher","unstructured":"Chua GT, Rosa Duque JS, Chong PCY, Lee PPW, Lau YL, Ho MHK. Paediatric case series of drug reaction with eosinophilia and systemic symptoms (DRESS): 12-year experience at a single referral centre in Hong Kong and the first reported use of infliximab. Eur Ann Allergy Clin Immunol. 2018;50(6):273\u20136. https:\/\/doi.org\/10.23822\/EurAnnACI.1764-1489.47.","DOI":"10.23822\/EurAnnACI.1764-1489.47"},{"issue":"1","key":"2354_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000388","volume":"8","author":"N Maximova","year":"2020","unstructured":"Maximova N, Maestro A, Zanon D, Marcuzzi A. Rapid recovery of postnivolumab vemurafenib-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome after tocilizumab and infliximab administration. J Immunother Cancer. 2020;8(1):e000388. https:\/\/doi.org\/10.1136\/jitc-2019-000388.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"2354_CR61","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1365-2230.2012.04357.x","volume":"37","author":"F Worsnop","year":"2012","unstructured":"Worsnop F, Wee J, Natkunarajah J, Moosa Y, Marsden R. Reaction to biological drugs: infliximab for the treatment of toxic epidermal necrolysis subsequently triggering erosive lichen planus. Clin Exp Dermatol. 2012;37(8):879\u201381. https:\/\/doi.org\/10.1111\/j.1365-2230.2012.04357.x.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"2354_CR62","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1111\/j.1365-2133.2004.06282.x","volume":"151","author":"M Dumont-Berset","year":"2004","unstructured":"Dumont-Berset M, Laffitte E, Gerber C, Dudler J, Panizzon RG. Eczematous drug eruption after infliximab. Br J Dermatol. 2004;151(6):1272\u20133. https:\/\/doi.org\/10.1111\/j.1365-2133.2004.06282.x.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2354_CR63","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/bcp.16390","volume":"91","author":"M Mokos","year":"2025","unstructured":"Mokos M, Bulat V, Liki\u0107 R, Bosni\u0107 F, Ga\u0161parov S. Infliximab-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) in a patient with ulcerative colitis. Br J Clin Pharmacol. 2025;91(3):903\u20137. https:\/\/doi.org\/10.1111\/bcp.16390.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2354_CR64","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/ajd.13911","volume":"63","author":"A Kherlopian","year":"2022","unstructured":"Kherlopian A, Mewton E, Fong G, Fischer G. Highlighting adalimumab as a treatment option for systemic treatment of toxic epidermal necrolysis: a case series from a tertiary specialised burns centre. Australas J Dermatol. 2022;63(4):497\u2013504. https:\/\/doi.org\/10.1111\/ajd.13911.","journal-title":"Australas J Dermatol"},{"key":"2354_CR65","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2147\/ccid.S401286","volume":"16","author":"L Zhang","year":"2023","unstructured":"Zhang L, Wu Z. Adalimumab for Sintilimab-induced toxic epidermal necrolysis in a patient with metastatic gastric malignancy: a case report and literature review. Clin Cosmet Investig Dermatol. 2023;16:457\u201361. https:\/\/doi.org\/10.2147\/ccid.S401286.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2354_CR66","doi-asserted-by":"publisher","first-page":"1188523","DOI":"10.3389\/fimmu.2023.1188523","volume":"14","author":"PY Chen","year":"2023","unstructured":"Chen PY, Li ZY, Cai SQ. Case report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental adalimumab. Front Immunol. 2023;14:1188523. https:\/\/doi.org\/10.3389\/fimmu.2023.1188523.","journal-title":"Front Immunol"},{"key":"2354_CR67","doi-asserted-by":"publisher","first-page":"3875024","DOI":"10.1155\/2020\/3875024","volume":"2020","author":"J Roselli","year":"2020","unstructured":"Roselli J, Innocenti T, Lynch EN, Parisio L, Apolito P, Mello T, et al. Stevens\u2013Johnson syndrome and herpes simplex type 1 infection during adalimumab therapy for Crohn\u2019s disease. Case Rep Gastrointest Med. 2020;2020:3875024. https:\/\/doi.org\/10.1155\/2020\/3875024.","journal-title":"Case Rep Gastrointest Med"},{"issue":"5","key":"2354_CR68","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00296-011-2212-4","volume":"33","author":"A Mounach","year":"2013","unstructured":"Mounach A, Rezqi A, Nouijai A, Ghozlani I, Achemlal L, Maghraoui AE, et al. Stevens\u2013Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease. Rheumatol Int. 2013;33(5):1351\u20133. https:\/\/doi.org\/10.1007\/s00296-011-2212-4.","journal-title":"Rheumatol Int"},{"issue":"35","key":"2354_CR69","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.3748\/wjg.15.4449","volume":"15","author":"M Salama","year":"2009","unstructured":"Salama M, Lawrance IC. Stevens\u2013Johnson syndrome complicating adalimumab therapy in Crohn\u2019s disease. World J Gastroenterol. 2009;15(35):4449\u201352. https:\/\/doi.org\/10.3748\/wjg.15.4449.","journal-title":"World J Gastroenterol"},{"key":"2354_CR70","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/ccid.S391979","volume":"16","author":"L Deng","year":"2023","unstructured":"Deng L, He B, Ali K, Bu Z. Terbinafine induced acute generalized exanthematous pustulosis treated with adalimumab: recalcitrant to systemic corticosteroid therapy. Clin Cosmet Investig Dermatol. 2023;16:9\u201315. https:\/\/doi.org\/10.2147\/ccid.S391979.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"2354_CR71","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/ced.14400","volume":"46","author":"S Bhadresha","year":"2021","unstructured":"Bhadresha S, Hughes AJ, McMahon L, Reeken S, Natkunarajah N. Fixed drug eruption secondary to adalimumab. Clin Exp Dermatol. 2021;46(2):366\u20138. https:\/\/doi.org\/10.1111\/ced.14400.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"2354_CR72","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1684\/ejd.2016.2898","volume":"27","author":"A Inoue","year":"2017","unstructured":"Inoue A, Sawada Y, Yamaguchi T, Ohmori S, Omoto D, Haruyama S, et al. Lichenoid drug eruption caused by adalimumab: a case report and literature review. Eur J Dermatol. 2017;27(1):69\u201370. https:\/\/doi.org\/10.1684\/ejd.2016.2898.","journal-title":"Eur J Dermatol"},{"issue":"3","key":"2354_CR73","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1089\/derm.2023.0110","volume":"35","author":"M Lei","year":"2024","unstructured":"Lei M, Niu R, Cheng X, Zhang X, Xue S, Yang Y. Erythema multiforme-like drug eruption associated with adalimumab treatment. Dermatitis. 2024;35(3):310\u20132. https:\/\/doi.org\/10.1089\/derm.2023.0110.","journal-title":"Dermatitis"},{"issue":"2","key":"2354_CR74","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaci.2022.06.012","volume":"150","author":"A Shankar","year":"2022","unstructured":"Shankar A, McAlees JW, Lewkowich IP. Modulation of IL-4\/IL-13 cytokine signaling in the context of allergic disease. J Allergy Clin Immunol. 2022;150(2):266\u201376. https:\/\/doi.org\/10.1016\/j.jaci.2022.06.012.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2354_CR75","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","volume":"50","author":"H Harb","year":"2020","unstructured":"Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020;50(1):5\u201314. https:\/\/doi.org\/10.1111\/cea.13491.","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"2354_CR76","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.alit.2020.01.002","volume":"69","author":"K Matsunaga","year":"2020","unstructured":"Matsunaga K, Katoh N, Fujieda S, Izuhara K, Oishi K. Dupilumab: basic aspects and applications to allergic diseases. Allergol Int. 2020;69(2):187\u201396. https:\/\/doi.org\/10.1016\/j.alit.2020.01.002.","journal-title":"Allergol Int"},{"key":"2354_CR77","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jdcr.2024.03.020","volume":"48","author":"K Valido","year":"2024","unstructured":"Valido K, Patel V, Murphy MJ, Junejo MH, Patel DK, Deutsch A, et al. Treatment of prolonged drug reaction with eosinophilia and systemic symptoms syndrome with dupilumab using a molecularly-guided approach. JAAD Case Rep. 2024;48:49\u201353. https:\/\/doi.org\/10.1016\/j.jdcr.2024.03.020.","journal-title":"JAAD Case Rep"},{"key":"2354_CR78","doi-asserted-by":"publisher","unstructured":"Shen C, Wu N, Yang L, Wang B, Liu T, Tao J. Dupilumab as effective therapy for corticosteroid-dependent\/resistant type 2 inflammation-related cutaneous adverse reactions. J Investig Allergol Clin Immunol. 2024;34(2):145\u20137. https:\/\/doi.org\/10.18176\/jiaci.0944.","DOI":"10.18176\/jiaci.0944"},{"issue":"12","key":"2354_CR79","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1016\/j.jaip.2023.08.028","volume":"11","author":"DP Dubin","year":"2023","unstructured":"Dubin DP, Yassky D, Poplausky D, Young JN, Tan KJ, Gulati N. Dupilumab to treat drug reaction with eosinophilia and systemic symptoms: a case series. J Allergy Clin Immunol Pract. 2023;11(12):3789\u201391. https:\/\/doi.org\/10.1016\/j.jaip.2023.08.028.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"2354_CR80","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/bjd\/ljad149","volume":"189","author":"WD Shipman","year":"2023","unstructured":"Shipman WD, Singh K, Cohen JM, Leventhal J, Damsky W, Tomayko MM. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. Br J Dermatol. 2023;189(3):339\u201341. https:\/\/doi.org\/10.1093\/bjd\/ljad149.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2354_CR81","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/bjd\/ljae403","volume":"192","author":"N Planella-Fontanillas","year":"2025","unstructured":"Planella-Fontanillas N, Bosch-Amate X, Jim\u00e9nez Ant\u00f3n A, Moreno-V\u00edlchez C, Guerrero MG, Blanes Mart\u00ednez MDM, et al. Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series. Br J Dermatol. 2025;192(3):501\u20139. https:\/\/doi.org\/10.1093\/bjd\/ljae403.","journal-title":"Br J Dermatol"},{"issue":"8","key":"2354_CR82","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15623","volume":"35","author":"SR Pop","year":"2022","unstructured":"Pop SR, Strock D, Smith RJ. Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: a case report. Dermatol Ther. 2022;35(8):e15623. https:\/\/doi.org\/10.1111\/dth.15623.","journal-title":"Dermatol Ther"},{"key":"2354_CR83","doi-asserted-by":"publisher","unstructured":"Klepper EM, Robinson HN. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature. Dermatol Online J. 2021. https:\/\/doi.org\/10.5070\/d327955136.","DOI":"10.5070\/d327955136"},{"issue":"6","key":"2354_CR84","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.jaad.2025.08.008","volume":"93","author":"M Azin","year":"2025","unstructured":"Azin M, Farokh P, McGarry A, Leung BW, Roster K, Rashdan H, et al. Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitors. J Am Acad Dermatol. 2025;93(6):1456\u201363. https:\/\/doi.org\/10.1016\/j.jaad.2025.08.008.","journal-title":"J Am Acad Dermatol"},{"key":"2354_CR85","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jdcr.2021.05.037","volume":"14","author":"NA Trum","year":"2021","unstructured":"Trum NA, Zain J, Abad C, Rosen ST, Querfeld C. Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash. JAAD Case Rep. 2021;14:37\u201342. https:\/\/doi.org\/10.1016\/j.jdcr.2021.05.037.","journal-title":"JAAD Case Rep."},{"key":"2354_CR86","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jdcr.2023.05.036","volume":"38","author":"SK Zemlok","year":"2023","unstructured":"Zemlok SK, Buuh S, Brown R, Murphy M, Hegde UP, Mallett JR. Nivolumab-induced lichen planus responsive to dupilumab treatment in a patient with stage III C melanoma. JAAD Case Rep. 2023;38:23\u20136. https:\/\/doi.org\/10.1016\/j.jdcr.2023.05.036.","journal-title":"JAAD Case Rep."},{"key":"2354_CR87","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jdcr.2022.01.029","volume":"22","author":"E Shelton","year":"2022","unstructured":"Shelton E, Doolittle C, Shinohara MM, Thompson JA, Moshiri AS. Can\u2019t handle the itch? Refractory immunotherapy-related transient acantholytic dermatosis: prompt resolution with dupilumab. JAAD Case Rep. 2022;22:31\u20133. https:\/\/doi.org\/10.1016\/j.jdcr.2022.01.029.","journal-title":"JAAD Case Rep."},{"issue":"6","key":"2354_CR88","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15117","volume":"34","author":"L Mastorino","year":"2021","unstructured":"Mastorino L, Ortoncelli M, Virginia B, Rolla G, Avallone G, Cavaliere G, et al. Dupilumab-induced urticaria. Dermatol Ther. 2021;34(6):e15117. https:\/\/doi.org\/10.1111\/dth.15117.","journal-title":"Dermatol Ther"},{"issue":"1","key":"2354_CR89","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/pde.14434","volume":"38","author":"AL Fritz","year":"2021","unstructured":"Fritz AL, Lacy FA, Morrell DS. Angioedema: a potential complication of dupilumab in atopic dermatitis. Pediatr Dermatol. 2021;38(1):237\u20138. https:\/\/doi.org\/10.1111\/pde.14434.","journal-title":"Pediatr Dermatol"},{"key":"2354_CR90","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.2245","volume":"102","author":"M Wang","year":"2022","unstructured":"Wang M, Zheng Q, Tang S, Shen F, Jiang W. Purpuric drug eruption in a patient with atopic dermatitis treated with dupilumab. Acta Derm Venereol. 2022;102:adv00744. https:\/\/doi.org\/10.2340\/actadv.v102.2245.","journal-title":"Acta Derm Venereol"},{"key":"2354_CR91","doi-asserted-by":"publisher","first-page":"adv37804","DOI":"10.2340\/actadv.v104.37804","volume":"104","author":"A Kaneoka","year":"2024","unstructured":"Kaneoka A, Saito-Sasaki N, Sakuragi Y, Sawada Y. Fixed drug eruption due to dupilumab. Acta Derm Venereol. 2024;104:adv37804. https:\/\/doi.org\/10.2340\/actadv.v104.37804.","journal-title":"Acta Derm Venereol"},{"key":"2354_CR92","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jdcr.2021.04.035","volume":"13","author":"TE Kim","year":"2021","unstructured":"Kim TE, Shin MK. De novo case of lichenoid eruption following dupilumab treatment. JAAD Case Rep. 2021;13:71\u20132. https:\/\/doi.org\/10.1016\/j.jdcr.2021.04.035.","journal-title":"JAAD Case Rep."},{"issue":"11","key":"2354_CR93","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15792","volume":"35","author":"XH Long","year":"2022","unstructured":"Long XH, Jiang HS, Lai JD, Liu YH, Wang WL. Erythema multiforme-like drug eruption associated with dupilumab treatment: report of an unusual case. Dermatol Ther. 2022;35(11):e15792. https:\/\/doi.org\/10.1111\/dth.15792.","journal-title":"Dermatol Ther"},{"key":"2354_CR94","doi-asserted-by":"publisher","first-page":"adv00743","DOI":"10.2340\/actadv.v102.1079","volume":"102","author":"L Wu","year":"2022","unstructured":"Wu L, Ali K, Qiu Y, Li M, Da J. Dupilumab-induced acute generalized exanthematous pustulosis in a 17-year-old female Chinese patient with atopic dermatitis. Acta Derm Venereol. 2022;102:adv00743. https:\/\/doi.org\/10.2340\/actadv.v102.1079.","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"2354_CR95","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jdcr.2018.05.014","volume":"4","author":"EH Tracey","year":"2018","unstructured":"Tracey EH, Elston C, Feasel P, Piliang M, Michael M, Vij A. Erythrodermic presentation of psoriasis in a patient treated with dupilumab. JAAD Case Rep. 2018;4(7):708\u201310. https:\/\/doi.org\/10.1016\/j.jdcr.2018.05.014.","journal-title":"JAAD Case Rep."},{"issue":"1","key":"2354_CR96","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1111\/jdv.16782","volume":"35","author":"R Treudler","year":"2021","unstructured":"Treudler R, Delaroque N, Puder M, Simon JC, Szardenings M. Dupilumab-induced serum sickness-like reaction: an unusual adverse effect in a patient with atopic eczema. J Eur Acad Dermatol Venereol. 2021;35(1):e30\u20132. https:\/\/doi.org\/10.1111\/jdv.16782.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2354_CR97","doi-asserted-by":"publisher","DOI":"10.1007\/s40629-022-00224-7","author":"A Gschwend","year":"2022","unstructured":"Gschwend A, Helbling A, Feldmeyer L, Mani-Weber U, Meincke C, Heidemeyer K, et al. Treatment with IL5-\/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS). Allergo J Int. 2022. https:\/\/doi.org\/10.1007\/s40629-022-00224-7.","journal-title":"Allergo J Int."},{"issue":"3","key":"2354_CR98","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1159\/000519471","volume":"14","author":"H Park","year":"2021","unstructured":"Park H, Choi GS, Lee EM. Successful treatment of imatinib-induced DRESS syndrome using reslizumab without cessation of imatinib: a case report. Case Rep Oncol. 2021;14(3):1548\u201354. https:\/\/doi.org\/10.1159\/000519471.","journal-title":"Case Rep Oncol"},{"key":"2354_CR99","doi-asserted-by":"publisher","first-page":"1255533","DOI":"10.3389\/fimmu.2023.1255533","volume":"14","author":"E Grebenciucova","year":"2023","unstructured":"Grebenciucova E, VanHaerents S. Interleukin 6: at the interface of human health and disease. Front Immunol. 2023;14:1255533. https:\/\/doi.org\/10.3389\/fimmu.2023.1255533.","journal-title":"Front Immunol"},{"issue":"1","key":"2354_CR100","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamadermatol.2022.5146","volume":"159","author":"M Blaise","year":"2023","unstructured":"Blaise M, Cardot-Leccia N, Seitz-Polski B, Picard-Gauci A, Bertold C, Passeron T, et al. Tocilizumab for corticosteroid-refractory immune checkpoint inhibitor-induced generalized morphea. JAMA Dermatol. 2023;159(1):112\u20134. https:\/\/doi.org\/10.1001\/jamadermatol.2022.5146.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2354_CR101","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/bjd.19129","volume":"183","author":"BP Hibler","year":"2020","unstructured":"Hibler BP, Markova A. Treatment of severe cutaneous adverse reaction with tocilizumab. Br J Dermatol. 2020;183(4):785\u20137. https:\/\/doi.org\/10.1111\/bjd.19129.","journal-title":"Br J Dermatol"},{"key":"2354_CR102","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/517424","volume":"2012","author":"JH Izquierdo","year":"2012","unstructured":"Izquierdo JH, Bonilla-Abad\u00eda F, Ochoa CD, Agualimpia A, Tob\u00f3n GJ, Ca\u00f1as CA. Acute generalized exanthematous pustulosis due to tocilizumab in a rheumatoid arthritis patient. Case Rep Rheumatol. 2012;2012:517424. https:\/\/doi.org\/10.1155\/2012\/517424.","journal-title":"Case Rep Rheumatol."},{"issue":"4","key":"2354_CR103","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7662","volume":"12","author":"N Venkateswaran","year":"2020","unstructured":"Venkateswaran N, Khianey R, Generoso A. Stevens Johnson syndrome in a patient with giant cell arteritis during short term tocilizumab therapy. Cureus. 2020;12(4):e7662. https:\/\/doi.org\/10.7759\/cureus.7662.","journal-title":"Cureus."},{"issue":"3","key":"2354_CR104","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jaip.2017.08.041","volume":"6","author":"B Ben Said","year":"2018","unstructured":"Ben Said B, Gerfaud-Valentin M, Seve P. Fatal DRESS syndrome under tocilizumab treatment for seronegative polyarthritis. J Allergy Clin Immunol Pract. 2018;6(3):1048\u20139. https:\/\/doi.org\/10.1016\/j.jaip.2017.08.041.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"2354_CR105","doi-asserted-by":"publisher","first-page":"141","DOI":"10.7326\/l16-0592","volume":"167","author":"E Zuelgaray","year":"2017","unstructured":"Zuelgaray E, Domont F, Peiffer-Smadja N, Saadoun D, Cacoub P. Tocilizumab-induced drug reaction with eosinophilia and systemic symptoms syndrome in adult-onset still disease. Ann Intern Med. 2017;167(2):141\u20132. https:\/\/doi.org\/10.7326\/l16-0592.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2354_CR106","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rky029","volume":"2","author":"RI Massolino","year":"2018","unstructured":"Massolino RI, Hissaria P, Lee A, Proudman SM. Tocilizumab-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient with rheumatoid arthritis. Rheumatol Adv Pract. 2018;2(2):rky029. https:\/\/doi.org\/10.1093\/rap\/rky029.","journal-title":"Rheumatol Adv Pract"},{"issue":"1","key":"2354_CR107","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5070\/d329160215","volume":"29","author":"L Gleason","year":"2023","unstructured":"Gleason L, Hunter E, Cohen A, Suriano J, Nikbakht N. Atezolizumab-induced psoriasiform drug eruption successfully treated with ixekizumab: a case report and literature review. Dermatol Online J. 2023;29(1):12. https:\/\/doi.org\/10.5070\/d329160215.","journal-title":"Dermatol Online J"},{"issue":"4","key":"2354_CR108","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1089\/derm.2023.0208","volume":"35","author":"M Li","year":"2024","unstructured":"Li M, Yu S, Zhang G, Xie Y, Wei JC. Interleukin-17 monoclonal antibody successfully treated psoriasiform drug eruption induced by immune checkpoint inhibitors: a case report and review of literature. Dermatitis. 2024;35(4):410\u20132. https:\/\/doi.org\/10.1089\/derm.2023.0208.","journal-title":"Dermatitis"},{"issue":"7","key":"2354_CR109","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jdcr.2020.05.014","volume":"6","author":"M Munshi","year":"2020","unstructured":"Munshi M, Junge A, Gadaldi K, Yawalkar N, Heidemeyer K. Ixekizumab for treatment of refractory acute generalized exanthematous pustulosis caused by hydroxychloroquine. JAAD Case Rep. 2020;6(7):634\u20136. https:\/\/doi.org\/10.1016\/j.jdcr.2020.05.014.","journal-title":"JAAD Case Rep."},{"issue":"6","key":"2354_CR110","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.jaip.2020.01.045","volume":"8","author":"B Gualtieri","year":"2020","unstructured":"Gualtieri B, Solimani F, Hertl M, Buhl T, M\u00f6bs C, Pf\u00fctzner W. Interleukin 17 as a therapeutic target of acute generalized exanthematous pustulosis (AGEP). J Allergy Clin Immunol Pract. 2020;8(6):2081-4.e2. https:\/\/doi.org\/10.1016\/j.jaip.2020.01.045.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"2354_CR111","doi-asserted-by":"publisher","first-page":"e769","DOI":"10.1111\/jdv.19875","volume":"38","author":"Y Wang","year":"2024","unstructured":"Wang Y, Liu Y, Feng C, Wang M, Wang Q, Geng S. Hydroxychloroquine-induced acute generalized exanthematous pustulosis (AGEP) treated with secukinumab. J Eur Acad Dermatol Venereol. 2024;38(9):e769\u201371. https:\/\/doi.org\/10.1111\/jdv.19875.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"2354_CR112","doi-asserted-by":"publisher","first-page":"196","DOI":"10.18176\/jiaci.0946","volume":"34","author":"J Wen","year":"2024","unstructured":"Wen J, Wang Y, Wang B, Jiang B, Lan J, Yang J, et al. Rapid clearance of corticosteroid-resistant targetoid acute generalized exanthematous pustulosis using an IL-17A inhibitor: a case report. J Investig Allergol Clin Immunol. 2024;34(3):196\u20137. https:\/\/doi.org\/10.18176\/jiaci.0946.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"8","key":"2354_CR113","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15599","volume":"35","author":"J Liang","year":"2022","unstructured":"Liang J, Zhang S, Li Q, Yu Y, Chen X, Zhang X. Review of secukinumab-induced adverse events of special interest and its potential pathogenesis. Dermatol Ther. 2022;35(8):e15599. https:\/\/doi.org\/10.1111\/dth.15599.","journal-title":"Dermatol Ther"},{"issue":"5","key":"2354_CR114","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.271","volume":"3","author":"A Kaneoka","year":"2023","unstructured":"Kaneoka A, Saito-Sasaki N, Okada E, Sawada Y. Ixekizumab-induced urticarial drug eruption. Skin Health Dis. 2023;3(5):e271. https:\/\/doi.org\/10.1002\/ski2.271.","journal-title":"Skin Health Dis."},{"key":"2354_CR115","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3389\/fcell.2019.00317","volume":"7","author":"D Queen","year":"2019","unstructured":"Queen D, Ediriweera C, Liu L. Function and regulation of IL-36 signaling in inflammatory diseases and cancer development. Front Cell Dev Biol. 2019;7:317. https:\/\/doi.org\/10.3389\/fcell.2019.00317.","journal-title":"Front Cell Dev Biol."},{"key":"2354_CR116","doi-asserted-by":"publisher","first-page":"adv41311","DOI":"10.2340\/actadv.v104.41311","volume":"104","author":"G Russo","year":"2024","unstructured":"Russo G, Dumont S, Menzinger S, Pastor D, Toutous Trellu L, Kaya G, et al. Severe acute generalized exanthematous pustulosis successfully treated by spesolimab. Acta Derm Venereol. 2024;104:adv41311. https:\/\/doi.org\/10.2340\/actadv.v104.41311.","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"2354_CR117","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1001\/jamadermatol.2024.2311","volume":"160","author":"Y Xuan","year":"2024","unstructured":"Xuan Y, Jin S, Zhang C, Wang S. Rapid improvement in refractory acute generalized exanthematous pustulosis with spesolimab. JAMA Dermatol. 2024;160(9):1009\u201312. https:\/\/doi.org\/10.1001\/jamadermatol.2024.2311.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"2354_CR118","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1111\/all.14908","volume":"76","author":"MH Shamji","year":"2021","unstructured":"Shamji MH, Valenta R, Jardetzky T, Verhasselt V, Durham SR, W\u00fcrtzen PA, et al. The role of allergen-specific IgE, IgG and IgA in allergic disease. Allergy. 2021;76(12):3627\u201341. https:\/\/doi.org\/10.1111\/all.14908.","journal-title":"Allergy"},{"issue":"6","key":"2354_CR119","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.annonc.2021.02.016","volume":"32","author":"DM Barrios","year":"2021","unstructured":"Barrios DM, Phillips GS, Geisler AN, Trelles SR, Markova A, Noor SJ, et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol. 2021;32(6):736\u201345. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.016.","journal-title":"Ann Oncol"},{"key":"2354_CR120","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.2147\/ccid.S487711","volume":"17","author":"J Chen","year":"2024","unstructured":"Chen J, Xu D, He Z, Ma S, Liu J, Dai X, et al. Successful treatment of immune checkpoint inhibitor-induced bullous pemphigoid with omalizumab: a case report and review of the literature. Clin Cosmet Investig Dermatol. 2024;17:2865\u201374. https:\/\/doi.org\/10.2147\/ccid.S487711.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2354_CR121","doi-asserted-by":"publisher","first-page":"666","DOI":"10.12659\/ajcr.899823","volume":"17","author":"R Uzun","year":"2016","unstructured":"Uzun R, Yalcin AD, Celik B, Bulut T, Yalcin AN. Levofloxacin induced toxic epidermal necrolysis: successful therapy with omalizumab (anti-IgE) and pulse prednisolone. Am J Case Rep. 2016;17:666\u201371. https:\/\/doi.org\/10.12659\/ajcr.899823.","journal-title":"Am J Case Rep"},{"issue":"3","key":"2354_CR122","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3109\/08923973.2016.1173057","volume":"38","author":"AD Yalcin","year":"2016","unstructured":"Yalcin AD, Celik B, Yalcin AN. Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels. Immunopharmacol Immunotoxicol. 2016;38(3):253\u20136. https:\/\/doi.org\/10.3109\/08923973.2016.1173057.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"1","key":"2354_CR123","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jaip.2023.09.036","volume":"12","author":"B Ben Said","year":"2024","unstructured":"Ben Said B, Dupire G, Poutrel S, Jullien D. The usefulness of omalizumab in low response to corticosteroids DRESS syndrome: a case series. J Allergy Clin Immunol Pract. 2024;12(1):236\u20138. https:\/\/doi.org\/10.1016\/j.jaip.2023.09.036.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"2354_CR124","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13542","volume":"33","author":"F Kemeriz","year":"2020","unstructured":"Kemeriz F, Acar EM, Ordu M. Omalizumab induced lichenoid drug eruption triggered by sun exposure. Dermatol Ther. 2020;33(4):e13542. https:\/\/doi.org\/10.1111\/dth.13542.","journal-title":"Dermatol Ther"},{"issue":"2","key":"2354_CR125","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40257-022-00751-7","volume":"24","author":"S Ly","year":"2023","unstructured":"Ly S, Nedosekin D, Wong HK. Review of an anti-CD20 monoclonal antibody for the treatment of autoimmune diseases of the skin. Am J Clin Dermatol. 2023;24(2):247\u201373. https:\/\/doi.org\/10.1007\/s40257-022-00751-7.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"2354_CR126","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jaad.2022.06.1186","volume":"88","author":"JT Said","year":"2023","unstructured":"Said JT, Talia J, Wei E, Mostaghimi A, Semenov Y, Giobbie-Hurder A, et al. Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor-induced bullous pemphigoid. J Am Acad Dermatol. 2023;88(3):670\u20131. https:\/\/doi.org\/10.1016\/j.jaad.2022.06.1186.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2354_CR127","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/ijd.15366","volume":"60","author":"S Kaul","year":"2021","unstructured":"Kaul S, Wang A, Grushchak S, Albrecht J. Pembrolizumab-induced reactivation of bullous pemphigoid. Int J Dermatol. 2021;60(6):757\u20138. https:\/\/doi.org\/10.1111\/ijd.15366.","journal-title":"Int J Dermatol"},{"key":"2354_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.572863","volume":"11","author":"GE Fouda","year":"2020","unstructured":"Fouda GE, Bavbek S. Rituximab hypersensitivity: from clinical presentation to management. Front Pharmacol. 2020;11:572863. https:\/\/doi.org\/10.3389\/fphar.2020.572863.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2354_CR129","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1111\/ijd.15706","volume":"61","author":"M Daneshpazhooh","year":"2022","unstructured":"Daneshpazhooh M, Tavakolpour S, Salehi Farid A, Ebadi M, Nili A, Rashidian M, et al. Pustular eruption after biosimilar rituximab infusion: report of acute generalized exanthematous pustulosis in two patients with pemphigus. Int J Dermatol. 2022;61(1):e14\u20137. https:\/\/doi.org\/10.1111\/ijd.15706.","journal-title":"Int J Dermatol"},{"issue":"4","key":"2354_CR130","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","volume":"159","author":"PH Schafer","year":"2010","unstructured":"Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842\u201355. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00559.x.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2354_CR131","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14888","volume":"34","author":"T Miyagaki","year":"2021","unstructured":"Miyagaki T, Okano T, Nakajima K, Mitsuishi S, Kishi A, Miyano K, et al. A case of facial redness in atopic dermatitis occurring during dupilumab treatment successfully treated with topical delgocitinib ointment. Dermatol Ther. 2021;34(2):e14888. https:\/\/doi.org\/10.1111\/dth.14888.","journal-title":"Dermatol Ther"},{"issue":"5","key":"2354_CR132","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1684\/ejd.2021.4140","volume":"31","author":"K Kurihara","year":"2021","unstructured":"Kurihara K, Fujiyama T, Tokura Y, Honda T. Two cases of psoriasiform dermatitis arising during dupilumab therapy and successfully treated with delgocitinib ointment. Eur J Dermatol. 2021;31(5):658\u201360. https:\/\/doi.org\/10.1684\/ejd.2021.4140.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"2354_CR133","doi-asserted-by":"publisher","first-page":"2336118","DOI":"10.1080\/09546634.2024.2336118","volume":"35","author":"CM Powers","year":"2024","unstructured":"Powers CM, Verma H, Orloff J, Piontkowski AJ, Tiersten A, Lamb A, et al. Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report. J Dermatolog Treat. 2024;35(1):2336118. https:\/\/doi.org\/10.1080\/09546634.2024.2336118.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"2354_CR134","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/bjd\/ljae375","volume":"192","author":"TM Chiu","year":"2025","unstructured":"Chiu TM, Chen CB, Lu CW, Hui RC, Chi MH, Chang YC, et al. CCR8\/CCL1 and CXCR3\/CXCL10 axis-mediated memory T-cell activation in patients with recalcitrant drug-induced hypersensitivity. Br J Dermatol. 2025;192(2):293\u2013305. https:\/\/doi.org\/10.1093\/bjd\/ljae375.","journal-title":"Br J Dermatol"},{"issue":"12","key":"2354_CR135","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.jdcr.2019.07.004","volume":"5","author":"WE Damsky","year":"2019","unstructured":"Damsky WE, Vesely MD, Lee AI, Choi J, Meyer AC, Chen M, et al. Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib. JAAD Case Rep. 2019;5(12):1018\u201326. https:\/\/doi.org\/10.1016\/j.jdcr.2019.07.004.","journal-title":"JAAD Case Rep."},{"key":"2354_CR136","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2019.03.016","volume":"113","author":"CY Chen","year":"2019","unstructured":"Chen CY, Chiu CF, Bai LY. Treatment of pembrolizumab-induced cutaneous lesions with ruxolitinib. Eur J Cancer. 2019;113:69\u201371. https:\/\/doi.org\/10.1016\/j.ejca.2019.03.016.","journal-title":"Eur J Cancer"},{"issue":"7","key":"2354_CR137","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1093\/rheumatology\/keac694","volume":"62","author":"Y Fu","year":"2023","unstructured":"Fu Y, Li J, Xu A, Chen J, Wang X, Ye S. Ruxolitinib rescued the macrophage activation syndrome in adult-onset Still\u2019s disease with delayed hypersensitivity reaction to tocilizumab. Rheumatology (Oxford). 2023;62(7):e223\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/keac694.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"2354_CR138","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/der.0000000000000879","volume":"34","author":"WH Chung","year":"2023","unstructured":"Chung WH, Chen CB, Chan TM. Baricitinib treatment for palisaded neutrophilic granulomatous dermatitis: a new paradoxical reaction to tocilizumab. Dermatitis. 2023;34(5):466\u20137. https:\/\/doi.org\/10.1097\/der.0000000000000879.","journal-title":"Dermatitis"},{"issue":"5","key":"2354_CR139","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/ddg.15355","volume":"22","author":"A Magarreiro-Silva","year":"2024","unstructured":"Magarreiro-Silva A, Pimenta R, Gouveia AI, Mendes-Bastos P. Dupilumab-associated facial and neck dermatitis successfully treated with baricitinib. J Dtsch Dermatol Ges. 2024;22(5):704\u20135. https:\/\/doi.org\/10.1111\/ddg.15355.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"2354_CR140","doi-asserted-by":"publisher","first-page":"2242706","DOI":"10.1080\/09546634.2023.2242706","volume":"34","author":"J Zhang","year":"2023","unstructured":"Zhang J, Zuo YG. Successful treatment of alopecia universalis with abrocitinib: a case report. J Dermatolog Treat. 2023;34(1):2242706. https:\/\/doi.org\/10.1080\/09546634.2023.2242706.","journal-title":"J Dermatolog Treat"},{"issue":"9","key":"2354_CR141","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15713","volume":"35","author":"A Zabotti","year":"2022","unstructured":"Zabotti A, Giovannini I, De Vita S, Stinco G, Errichetti E. Recalcitrant and persistent adalimumab-induced paradoxical psoriasiform skin reaction in a rheumatoid arthritis patient successfully treated with upadacitinib. Dermatol Ther. 2022;35(9):e15713. https:\/\/doi.org\/10.1111\/dth.15713.","journal-title":"Dermatol Ther"},{"issue":"2","key":"2354_CR142","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.36849\/jdd.7645","volume":"23","author":"MJ Woodbury","year":"2024","unstructured":"Woodbury MJ, Grant C, Perez-Chada L, LaChance AH, Merola JF. A case series of TNF inhibitor-induced psoriasis successfully treated with upadacitinib. J Drugs Dermatol. 2024;23(2):e60\u20133. https:\/\/doi.org\/10.36849\/jdd.7645.","journal-title":"J Drugs Dermatol"},{"key":"2354_CR143","doi-asserted-by":"publisher","unstructured":"Gresham LM, Kirchhof MG. A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: a case report. SAGE Open Med Case Rep. 2023. https:\/\/doi.org\/10.1177\/2050313x231160926.","DOI":"10.1177\/2050313x231160926"},{"key":"2354_CR144","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2019.01.010","volume":"110","author":"D Fattore","year":"2019","unstructured":"Fattore D, Annunziata MC, Panariello L, Marasca C, Fabbrocini G. Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast. Eur J Cancer. 2019;110:107\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2019.01.010.","journal-title":"Eur J Cancer"},{"issue":"5","key":"2354_CR145","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.jaad.2020.05.112","volume":"83","author":"S Ravichandran","year":"2020","unstructured":"Ravichandran S, Kheterpal MK. Apremilast for the off-label treatment of lichenoid and interface dermatoses. J Am Acad Dermatol. 2020;83(5):1489\u201391. https:\/\/doi.org\/10.1016\/j.jaad.2020.05.112.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2354_CR146","doi-asserted-by":"publisher","first-page":"438","DOI":"10.4103\/jfmpc.jfmpc_499_23","volume":"13","author":"SC Shanmukhappa","year":"2024","unstructured":"Shanmukhappa SC, John W, Kevalramani V, Lokeshwaran S, Furtado S, Nosenoor M. Antitubercular drug-induced lichen planus: a case study with a mini literature review. J Family Med Prim Care. 2024;13(2):438\u201343. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_499_23.","journal-title":"J Family Med Prim Care."},{"issue":"4","key":"2354_CR147","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jdcr.2020.01.013","volume":"6","author":"S Chapman","year":"2020","unstructured":"Chapman S, Adelman M, Sullivan A, Mancuso J, Lim HW. Apremilast-associated drug reaction with eosinophilia and systemic symptoms. JAAD Case Rep. 2020;6(4):302\u20134. https:\/\/doi.org\/10.1016\/j.jdcr.2020.01.013.","journal-title":"JAAD Case Rep."},{"issue":"3","key":"2354_CR148","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jaad.2020.04.020","volume":"84","author":"LL Wang","year":"2021","unstructured":"Wang LL, Noe MH, Micheletti RG. Long-term sequelae from Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in a large retrospective cohort. J Am Acad Dermatol. 2021;84(3):784\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.020.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2354_CR149","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1001\/jamadermatol.2021.1136","volume":"157","author":"M Hoffman","year":"2021","unstructured":"Hoffman M, Chansky PB, Bashyam AR, Boettler MA, Challa N, Dominguez A, et al. Long-term physical and psychological outcomes of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis. JAMA Dermatol. 2021;157(6):712\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2021.1136.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"2354_CR150","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/bjd\/ljad234","volume":"189","author":"YM Chiu","year":"2023","unstructured":"Chiu YM, Chiu HY. Lifetime risk, life expectancy, loss-of-life expectancy and lifetime healthcare expenditure for Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019. Br J Dermatol. 2023;189(5):553\u201360. https:\/\/doi.org\/10.1093\/bjd\/ljad234.","journal-title":"Br J Dermatol"},{"issue":"5","key":"2354_CR151","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1001\/jamadermatol.2021.0326","volume":"157","author":"LL Thompson","year":"2021","unstructured":"Thompson LL, Krasnow NA, Chang MS, Yoon J, Li EB, Polyakov NJ, et al. Patterns of cutaneous and noncutaneous immune-related adverse events among patients with advanced cancer. JAMA Dermatol. 2021;157(5):577\u201382. https:\/\/doi.org\/10.1001\/jamadermatol.2021.0326.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"2354_CR152","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1203475420943260","volume":"25","author":"A Muntyanu","year":"2021","unstructured":"Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV. Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management. J Cutan Med Surg. 2021;25(1):59\u201376. https:\/\/doi.org\/10.1177\/1203475420943260.","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"2354_CR153","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jaad.2023.02.014","volume":"88","author":"N Nguyen","year":"2023","unstructured":"Nguyen N, Wan G, Ugwu-Dike P, Alexander NA, Raval N, Zhang S, et al. Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy. J Am Acad Dermatol. 2023;88(6):1308\u201316. https:\/\/doi.org\/10.1016\/j.jaad.2023.02.014.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2354_CR154","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jaad.2019.09.017","volume":"82","author":"AK Guzman","year":"2020","unstructured":"Guzman AK, Zhang M, Kwatra SG, Kaffenberger BH. Predictors of 30-day readmission in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a cross-sectional database study. J Am Acad Dermatol. 2020;82(2):303\u201310. https:\/\/doi.org\/10.1016\/j.jaad.2019.09.017.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2354_CR155","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ard-2023-223850","volume":"83","author":"M Bonelli","year":"2024","unstructured":"Bonelli M, Kerschbaumer A, Kastrati K, Ghoreschi K, Gadina M, Heinz LX, et al. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Ann Rheum Dis. 2024;83(2):139\u201360. https:\/\/doi.org\/10.1136\/ard-2023-223850.","journal-title":"Ann Rheum Dis"},{"key":"2354_CR156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928621","volume":"13","author":"P Cao","year":"2022","unstructured":"Cao P, Xu W, Zhang L. Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review. Front Immunol. 2022;13:928621. https:\/\/doi.org\/10.3389\/fimmu.2022.928621.","journal-title":"Front Immunol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02354-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02354-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02354-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:02:59Z","timestamp":1788242579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02354-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":156,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2354"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02354-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"XZ, YS, and JG conceived and designed the study. All authors contributed to literature collection. YY, YW, JZ, and YX analyzed and interpreted the data and drafted the manuscript. All authors critically revised the manuscript and approved the final version for publication.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}